|
Neuland Laboratories reported results for the first quarter of FY27.The company's total income for Q1FY27 stood at Rs. 650.1 crore, while PAT for Q1FY27 was at Rs. 147.4 crore.
The company's CMS revenues were driven by commercial molecules. The company's growth in new project orders which will be delivered over the course of this and next financial years. The company's EBITDA margin for Q1FY27 was at 35.5%.
The company's Specialty segment works on complex products and technologies, hence has a focused approach towards select customers
Saharsh Davuluri, CEO & MD, Neuland Laboratories stated, “Q1 FY27 was broadly in line with our expectations with encouraging performance from both CMS & GDS businesses and represents a good start to the year. While commercial products contributed to most of the revenue, we are seeing exciting developments in terms of the pipeline projects. The depth of customer conversations today is significantly stronger, and we are increasingly engaging on broader capability-led discussions rather than individual projects alone. Internally our focus now is on ensuring that we deliver consistently, build customer confidence and establish the foundation for long-term partnerships. Even as we have invested significantly over the last three years and all our significant Capex projects are proceeding according to plan, I believe the intensity of our investments will further increase based on the opportunities that available to us."
|